home / stock / prfx / prfx news

PRFX News and Press, PainReform Ltd. From 07/03/23

Stock Information
Company Name: PainReform Ltd.
Stock Symbol: PRFX
Market: NASDAQ
Website: painreform.com
Menu
PRFX PRFX Quote PRFX Short PRFX News PRFX Articles PRFX Message Board
Get PRFX Alerts

News, Short Squeeze, Breakout and More Instantly...
PRFX - Ensysce, Journey Medical top healthcare gainers; Protagonist, VBI Vaccines among losers

2023-07-03 10:30:53 ET Gainers: Ensysce Biosciences ( ENSC ) +20% . Journey Medical ( DERM ) +20% . Ventyx Biosciences ( VTYX ) +16% . PainReform ( PRFX ) +12% . iCAD ( ICAD ) +7% . Losers: Protagonist Therapeutics ( PTG...
PRFX - Tesla, Li Auto, Fidelity National Information Services among premarket gainers' pack

2023-07-03 08:41:08 ET PainReform ( PRFX ) +22% . Alvotech ( ALVO ) +19% . Ensysce Biosciences ( ENSC ) +12% . Alliance Entertainment ( AENT ) +10% . Great Ajax AJX +9% on plans to be acquired by Ellington Financial for $7.33...

PRFX - PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

TEL AVIV, Israel, June 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer ...

PRFX - PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

TEL AVIV, Israel, June 07, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a regulatory update on the second part of its Ph...
PRFX - PainReform's Phase 3 trial of PRF-110 shows positive results for Bunionectomy patients

2023-05-18 10:25:46 ET PainReform ( NASDAQ: PRFX ) reports positive pharmacokinetic (PK) data in Phase 3 trial of PRF-110 for bunionectomy patients. Maximum plasma ropivacaine concentrations (Cmax) in the study were approximately 10% of FDA safety limit. PRF-110 demonstrat...

PRFX - PainReform Announces Positive Pharmacokinetic (PK) Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

TEL AVIV, Israel, May 18, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive pharmacokinetic (PK) data in the first ...

PRFX - PainReform Provides Business Update for the First Quarter of 2023

TEL AVIV, Israel, May 15, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the first quarter end...
PRFX - PainReform CEO to Present at Aegis Virtual Conference on May 4th

TEL AVIV, Israel, May 02, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer o...

PRFX - PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

TEL AVIV, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the "Company"), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced positive safety results in the first part of its...

PRFX - PainReform CEO to Present at the Sequire Investor Summit in Puerto Rico on April 26th

TEL AVIV, Israel, April 17, 2023 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (" PainReform " or the " Company "), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer...
Previous 10 Next 10